Emergent BioSolutions' Otlertuzumab (TRU-016) Shows Positive Results in ... MarketWatch "Emergent is pleased with the data from Cohort 1 of this Phase 1b study that show the safety and activity of otlertuzumab in combination with rituximab," said Scott C. Stromatt, M.D., senior vice president and chief medical officer, Emergent BioSolutions. |
